ABSTRACT: Galactofuranose (Galf) is present in glycans critical for the virulence and viability of several pathogenic microbes, including Mycobacterium tuberculosis, yet the monosaccharide is absent from mammalian glycans. Uridine 5′-diphosphate-galactopyranose mutase (UGM) catalyzes the formation of UDP-Galf, which is required to produce Galfcontaining glycoconjugates. Inhibitors of UGM have therefore been sought, both as antimicrobial leads and as tools to delineate the roles of Galf in cells. Obtaining cell permeable UGM probes by either design or high throughput screens has been difficult, as has elucidating how UGM binds small molecule, noncarbohydrate inhibitors. To address these issues, we employed structure-based virtual screening to uncover new inhibitor chemotypes, including a triazolothiadiazine series. These compounds are among the most potent antimycobacterial UGM inhibitors described. They also facilitated determination of a UGM−small molecule inhibitor structure, which can guide optimization. A comparison of results from the computational screen and a high-throughput fluorescence polarization (FP) screen indicated that the scaffold hits from the former had been evaluated in the FP screen but missed. By focusing on promising compounds, the virtual screen rescued false negatives, providing a blueprint for generating new UGM probes and therapeutic leads.
T he monosaccharide D-galactofuranose (Galf) is found in cell surface glycoconjugates of many human pathogens, but it is absent from the mammalian glycome. 1 Glycans containing Galf residues in human pathogens can be required for virulence as with K. pneumoniae 2 or viability as in M. tuberculosis. 3 Enzymes involved in Galf metabolism are therefore potential targets for the treatment of human disease. Uridine 5′-diphosphate (UDP)-galactopyranose mutase (Glf, also known as UGM) generates the biosynthetic precursor for Galf incorporation. UGM possesses a flavin adenine dinucleotide (FAD) cofactor that it uses to catalyze ring contraction of UDP-galactopyranose (UDP-Galp) to form UDP-Galf 4−6 ( Figure 1a ). All organisms that generate Galf-containing glycans encode a UGM homologue. As a result, the gene encoding UGM has been linked to the virulence and viability of many infectious microbes, such as Mycobacterium tuberculosis, 3, 7 Klebsiella pneumoniae, 1, 8 Leishmania major, Aspergillus f umigatus, 9 and parasitic nematodes. 10, 11 The rise of multi-drug-resistant and extremely drug-resistant strains of M. tuberculosis 12 has prompted a search for new tuberculosis drug candidates and new druggable targets. UGM is essential, 3, 7 and the gene encoding it is highly conserved between strains. 13 UGM is required to generate the essential Galf polysaccharide known as the galactan, which is found within the thick and hydrophobic mycobacterial cell envelope.
14, 15 These features render the enzyme an attractive potential target. Moreover, the presence of UGM homologues in a variety of pathogens suggests that UGM inhibitors could be useful against multiple classes of microbes. 10,16−23 We set out to devise cell-permeable UGM inhibitors that could be used as therapeutic leads and probes of the roles of Galf-containing glycans.
A number of researchers have sought UGM inhibitors. 16,18−20,22,24−30 Though inhibitors have emerged, [18] [19] [20] 31 few have been shown to function against microbial pathogens. We previously developed a fluorescence polarization (FP) assay to identify competitive UGM inhibitors. 17, 19 When implemented in a high-throughout screen (HTS) of 16 000 compounds, it afforded a series of thiazolidinones with an overall "hit-rate" of 0.4%. 19, 20 The thiazolidinone leads, however, are susceptible to conjugate addition by biological thiols 20 and are classified as pan assay interference compounds (PAINS). 32 Scaffold hopping was used to find 2-aminothiazole inhibitors, 18 the most potent of which had an IC 50 of 7.2 μM and 37 μM against K. pneumoniae UGM and M. tuberculosis UGM enzymes, respectively. 16, 17 Despite their promising antimycobacterial activity, they suffer from low solubility and mammalian cell toxicity at levels near their minimum inhibitory concentrations (MICs). 16 We postulate that their off-target effects are a consequence of their modest potency. With no structures of UGM-small molecule inhibitor complexes to optimize potency, we sought new scaffolds by screening 320 000 compounds through the Molecular Libraries Small Molecule Repository (MLSMR). The screen had a low hit rate (0.06%) and afforded but one lead inhibitor (IC 50 > 250 μM) of the M. tuberculosis UGM (PubChem AID 504439).
The issues we encountered are emblematic of those impeding pharmacological targeting and inhibitor discovery for nucleotide-sugar-binding enzymes. Few assays amenable to HTS have been developed. The available assays often use binding as a proxy for catalysis, 19, 33 and screens of this type can have high false negative rates. The scarcity of inhibitors for enzymes that act on nucleotide-sugar substrates is also problematic as it is unclear what scaffolds might give rise to leads. In principle, structure-based virtual screens can address these challenges. 34 Docking can be used to evaluate large libraries of molecules to find those that physically fit a protein site. The world's available compounds may be sampled, via libraries such as ZINC, 35, 36 and screens of 3−6 million molecules can be routinely implemented that can sample chemotypes not represented in small HTS libraries. Because only a limited number of prioritized molecules from the library are ultimately tested, one can use more sensitive lowthroughput assays to evaluate candidate ligands. Nevertheless, docking screens have their own risks: testing so few molecules leads to docking false-negatives, 37 and the technique remains plagued by false positives. The methodological problems of approximate scoring functions and under-sampling of molecular degrees-of-freedom are still unresolved. 38, 39 Indeed, others have struggled to find productive inhibitors of UGM using virtual screening. 40 Despite the above caveats, the lack of progress in applying experimental HTS strategies motivated us to use DOCK3.6 41, 42 to virtually screen a database of 4.6 million commercially available compounds. 35, 36 Three compounds that inhibit UGM in vitro were identified. Structure-based optimization produced a class of competitive triazolothiadiazine UGM inhibitors. Notably, members of this class exhibit antimycobacterial activity in cell culture against M. tuberculosis and are some of the most potent UGM inhibitors described to date. They also inhibit eukaryotic UGMs, a class of enzymes for which no high throughput assays are available. Moreover, a compound from this new series facilitated the determination of the first X-ray structure of a UGM in complex with a nonsubstrate inhibitor. We anticipate that this structure can be used to further optimize the lead compounds.
■ RESULTS AND DISCUSSION Docking Screen. As a starting point for the screen, we examined the structures of UGM:UDP-Galp substrate complexes available in the Protein Data Bank. Structures of UGM homologues from two eukaryotic species (Aspergillus f umigatus 43 and Trypanosoma cruzi 44 ) and five different bacterial species 6,21,45−48 have been determined. Because we were seeking antimycobacterial agents, we focused on structures of UGMs in the active conformation from bacterial species. We therefore used the structure of the substrate-bound, flavinreduced K. pneumoniae UGM (PDB ID: 3INT) as our starting point. 46 In this form of the enzyme, a flexible loop (residues 166−178) is closed over the active site (Figure 1b) . To evaluate docking sampling parameters, we created 1700 propertymatched decoys 49 for 25 2-aminothiazole 18 and 13 thiazolidinone 20 UGM inhibitors ( Figure S1 ). A property-matched decoy is a molecule with the physical properties of a known ligand (here the 38 inhibitors) but with topological features that render it unlikely to bind the enzyme. A well-performing retrospective docking calculation will highly rank the true ligands and deprioritize the decoy moleculesthis strategy has long been used to calibrate docking calculations. 49 To quantify how well true ligands were separated from decoy molecules, we calculated an "adjusted log AUC" score, 42 a metric that emphasizes early enrichment of ligands ranked highly and corrects for what one would expect at random. For context, a random ranking of docked compounds yields an adjusted log AUC of zero, while values greater than 20 indicate good performance. The optimal docking configuration led to a log AUC of 34.5 overall. Though thiazolidinones, members of the PAINS, can act as UGM inhibitors, 20 they scored poorly by docking. In contrast, ligands from the 2-aminothiazole series (e.g., Figure 2 , ED103), had a log AUC of 54.8 ( Figure S2a ), indicating high early enrichment (i.e., more than 50% of the known 2-aminothiazole ligands ranked within the top 1% of the library).
The configuration generated for known UGM binders was used to dock a library of 4.6 million "lead-like" 50 molecules (250 < molecular weight <350; xLogP ≤ 3.5; number of rotatable bonds ≤7 35, 50 Figure S2b ).
Experimental Evaluation of Docking. A small collection of compounds representing novel, previously untested scaffolds was selected from the most highly ranked compounds for in vitro testing. Many sources of error can exist in large-scale automatic docking screens, from approximate and incomplete scoring functions to misrepresentation of compounds in databases. These and other factors are not considered in the scoring function and are more effectively evaluated by a trained investigator. High-ranking molecules were rejected due to the following criteria: unlikely ionization state at physiological pH values, no commercial source docked in a high-energy conformation or with unsatisfied polar interactions. They were also prioritized for their potential to interact with either of the two critical active site arginines 51 and a complementary fit to the binding site. Using these criteria, 13 compounds were chosen to test as UGM inhibitors ( Figure S3 ). These compounds had docking scores that ranked among the top 0.01% of the library.
We first tested compounds against the K. pneumoniae UGM using an HPLC activity assay. 52 We employed this enzyme homologue as its structure was used in the virtual screen. Of the six compounds blocking more than 25% of UGM activity at 100 μM, five exhibited dose-dependent inhibition (15−33% at 50 μM). At concentrations in this range, nonspecific inhibition can occur if compounds undergo colloidal aggregation. 53 To eliminate small molecules that act via this mechanism, the assay was repeated in the presence of detergent (0.025% Tween 80), and compounds (3, 11, 12) whose activity was severely diminished when detergent was present were not analyzed further ( Figure S4 ). Three compounds (6, 8, and 10; Figure  2b ) showed dose-dependent UGM inhibition and insensitivity to detergent, giving an overall hit rate of 23% (3 out of 13).
We further characterized the features of compounds 6 and 10 relevant for their inhibitory activity. When dynamic light scattering (DLS) was used to directly assess their propensity to aggregate, neither 6 nor 10 formed colloids at concentrations of 100 μM ( Figure S5 ). This finding is consistent with their inhibitory activity in the presence of detergent. Additionally, at 100 μM, neither compound inhibits AmpC β-lactamase, an enzyme effective in counter-screens for promiscuous aggregation. 54, 55 The FP assay indicated that compound 6 binds to K. pneumoniae UGM with K d = 43 ± 20 μM and compound 10 with K d = 6 ± 3 μM ( Figure S6 ).
To elucidate the structure−activity relationships (SARs) of compounds 6 and 10, commercially available analogs were purchased and tested ( Figure 3 ). One analog of 10 showed improved K. pneumoniae UGM inhibition ( Figure S7 ), but limited availability of additional analogs and the solubility of 10 deterred us from further pursuing this series. A focus on compound 6, however, proved productive. Lineweaver−Burk analysis indicated that compound 6 is a competitive inhibitor of K. pneumoniae UGM with a K i of 78 ± 31 μM ( Figure S8 ). Of the 11 analogs of 6 sourced for testing, nine showed better inhibition of K. pneumoniae UGM at 100 μM than the parent compound (Table 1) , and five had better K d values. The most active compounds, 19, 22, and 24, exhibited K d values of 18 ± 11 μM, 9 ± 5 μM, and 9 ± 4 μM, respectively (Figure 3a and Figure S9 ). Although these results were promising, previous studies have shown that series that begin as nonaggregators can drift into this mechanism upon optimization. 56 Analysis by DLS indicated that 19 and 24 form particles at 100 μM, but compound 22 did not ( Figure S5 ). Lineweaver−Burk analysis indicated that 22 is a competitive inhibitor of K. pneumoniae UGM (Figure 3c ).
Inhibitors Act on Multiple Species. We next compared the selectivity of the new inhibitors by evaluating them with UGMs from other pathogens. The UGMs from M. tuberculosis and C. diphtheriae share about 43% sequence identity with that from K. pneumoniae but share 76% identity with each other Figure 2 . Normalized inhibitory activity of predicted UGM ligands against the UGM from K. pneumoniae. (a) Thirteen commercially available, predicted inhibitors were tested for inhibition in an enzyme activity assay. 52 Error bars show standard deviation (n = 2). Limited solubility precluded the testing of compound 9 under these conditions. (b) Structures of compounds that displayed dose-dependent inhibition. Docking rank (out of 4.6 million) from the virtual screen is indicated in parentheses. See Figure S3 for the structures of all tested molecules.
(ClustalO; Figure S10 ). Eukaryotic UGMs from organisms such as Caenorhabditis elegans have low sequence identity with bacterial UGMs. 10 Structural studies of the bacterial and eukaryotic enzymes reveal some differences in substrate binding, 43 yet the general features of the UGM active site are highly conserved across species. 57 Consistent with this conservation, compound 22 inhibited all the UGM homologues tested. It was less effective for the C. elegans UGM (K i = 25 ± 8 μM), M. tuberculosis UGM (K i = 31 ± 18 μM), and C. diphtheriae UGM (K i = 77 ± 37 μM) than for the K. pneumoniae UGM (K i = 8 ± 3 μM; Figure 4 ). This trend was preserved other analogs from this series (Figure 4 ). Higher activity against the K. pneumoniae homologue may reflect the use of a K. pneumoniae UGM structure for the docking screen.
The ability of the triazolothiadiazines to block a nematode UGM is noteworthy, as the FP assay used in HTS to find prokaryotic UGM inhibitors is not applicable to eukaryotic UGMs. Specifically, the fluorescent UDP derivative used in the FP assay binds too weakly to eukaryotic UGMs to be useful in screening. Recent structural studies of the A. f umigatus UGM reveal that the substrate uracil adopts a conformation in the binding site 43 that differs from that observed with the prokaryotic enzymes. These distinctions may be important for FP probe binding and catalysis, but the use of the prokaryotic enzyme in the docking screen yielded inhibitors that act against both prokaryotic and eukaryotic UGM homologues.
X-ray Crystallography of a UGM−22 Complex. A major barrier to optimizing previously identified UGM inhibitors has been the lack of a UGM−inhibitor structure. We therefore used X-ray crystallography to determine a structure of UGM in complex with small molecule 22. Although we obtained crystals of the K. pneumoniae UGM in the presence of 22 that Table S1 for data collection and refinement statistics). Its modest resolution notwithstanding, the structure provides insight into the binding orientation and interactions of 22.
The UGM complex crystallized in the open, oxidized conformation. Co-crystals of C. diphtheriae UGM and 22 in the reduced, closed form of the enzyme were not obtained, but our structure shows some additional density proximal to the ligand that likely corresponds to the closed lid ( Figure S11 ). In both monomers (chain A and chain B), compound 22 binds in the active site (Figure 5a ; Figure S12 ). In both chains, the R 1 thiophene of 22 occupies a hydrophobic pocket formed by Tyr326, Tyr364, Trp162, and Pro327, while the R 2 chlorophenyl stacks on face-to-face with Tyr326 and edge-toface with Trp162. In chain A, there is a salt bridge between the carboxylate group of the inhibitor and Arg288, a residue essential for UGM activity. 51 In chain B, however, density for the ligand carboxylate is more ambiguous. Therefore, despite its marginally higher average temperature factors (106 versus 97 Å 2 ) and slightly lower occupancy (0.81 versus 0.87) (Table S1 ), we focused on the ligand in chain A in our structural analysis.
Comparison of X-ray Structure and Docking Pose. The structure provided a means to compare the docked ligand pose to that determined experimentally. The C. diphtheriae UGM− ligand complex determined by X-ray crystallography is in the open form rather than in the closed loop conformation of the K. pneumoniae UGM structure used for the docking screen. The difference is not surprising as X-ray structures of UGM bound to substrates or substrate analogs have captured the enzyme in both open and closed forms. 29 The key catalytic Arg174 residue is located on the flexible loop of UGM and thus moves into the substrate-binding pocket in the active form of the enzyme. 46, 51 Overlay of the X-ray structure of the UGM−inhibitor complex and the K. pneumoniae UGM structure employed in docking indicates that some reorientation of the Arg174-containing loop or of compound 22 would need to occur for 22 to bind the closed form of the enzyme (Figures 5c and S13) . The enzyme's flexibility leaves open the issue of whether compound 22 can bind to the closed conformation of the enzyme. This flexibility was also manifested when we examined the predicted docking pose of high-ranking hit 6: the ligand occupies the binding pocket present in the X-ray structure. The salt bridge between the inhibitor scaffold carboxylate and Arg288 (C. diphtheriae UGM numbering; Figure S12 ), seen in chain A also is predicted. Similarly, when 22 was computationally docked into C. diphtheriae UGM in the open conformation, the ligand pose matched that experimentally determined for chain A ( Figure  S14 ), suggesting that docking can capture the important features of binding to this conformation of the protein.
Though the orientation of compound 6 docked in the K. pneumoniae UGM active site differs somewhat from that in the X-ray structure of C. diphtheriae UGM, there are reasons to suspect that both of these are relevant to the activity of the series. 58 In both, the ligand carboxylate participates in an ionic interaction with Arg288 and interactions that occur with many of the conserved aromatic residues in the UGM−22 complex are observed in the docked model. Opposing conformations of the flexible loop ( Figure S13 ), sequence differences between K. pneumoniae UGM and C. diphtheriae UGM distal to the binding site, and the small variation in the ligand (6 versus 22) itself may contribute to discrepancies between the poses. Still, it seems likely that the hydrophobic subpockets of the binding site can support a large range of substitutions and/or binding modes. Interestingly, both ligand orientations are consistent with the observed SAR, as they indicate larger R 1 side-chains are favorable and that bulky R 2 para substitutions are preferred ( Figure S12 ). We anticipate that both the crystal structure and docking pose can guide inhibitor optimization.
The structure of C. diphtheriae UGM bound to compound 22 adds to the growing number of UGM structures from human pathogens. 6, 21, [44] [45] [46] 59, 60 Most significantly, however, it serves as the founding structure of a UGM bound to a small molecule, nonsubstrate inhibitor. Though the first UGM inhibitors were identified more than 10 years ago 23 and several small molecule inhibitors have been reported subsequently, [18] [19] [20] 31 no structures of a complex have been disclosed. Our success in obtaining a complex with the triazolothiadiazines provides guidance for augmenting UGM inhibitor potency.
Structure−Activity Relationship Analyses. The initial activities and ligand efficiency (LE = ΔG/Number of heavy atoms) values of 0.3 61 provides impetus for triazolothiadiazine optimization. We therefore analyzed the structure determined by X-ray crystallography and the predicted docking pose to optimize potency within this series (Table 1; Figure S12 ). We anticipated that ligands with larger or more polarizable para substituents on the R 2 phenyl ring would be more effective, and the SAR we had obtained to date are consistent with this analysis (i.e., pCl-Phe 26 > pMe-Phe 25 > pF-Phe 16). The parachlorophenyl substituent was expected to be especially favorable given the activities of 26 and 22. With regard to the R 1 substituent, we anticipated that larger groups would give rise to enhanced inhibitor potency, as we had observed (i.e., compound 19 > 18 > 17 and compound 22 > 21). We therefore tested five additional commercially available "second generation" analogs (compounds 27−31, Table 1 ). All secondgeneration analogs afforded more than 90% inhibition at 100 μM, with three of the five showing greater than 90% inhibition at 50 μM. It is interesting to note that both ligand orientations (docking and X-ray structure) are consistent with the observed SAR, as they indicate that larger R 1 side-chains are favorable and that bulky R 2 para substitutions are preferred ( Figure S12 ).
The best inhibitor (30) fully blocked K. pneumoniae UGM activity at 50 μM. We therefore characterized its binding to and inhibition of UGM (Figure 3b,d) . Compound 30 is a competitive inhibitor of K. pneumoniae UGM (K i = 1.1 ± 0.2 μM. The ability of 30 to block different UGM homologues followed the same relative order as observed with 22: K i values of 28 ± 15 μM, 29 ± 8 μM, and 7 ± 3 μM were obtained for the M. tuberculosis, C. diphtheriae, and C. elegans UGM, respectively ( Figure 4) . It is notable that compound 30 is substantially more active any of its analogs tested against all UGM homologues. We detected no colloidal aggregates ( Figure S5 ) nor nonspecific inhibition of malate dehydrogenase ( Figure S14 ) at relevant compound concentrations. Additionally, detergent had no effect on competitive binding of 30 to UGM ( Figure S15 ). Together, these data indicate that the inhibitory activity of 30 is specific.
Antimycobacterial activity of UGM inhibitors. For screens focused either on enzyme binding or inhibition in solution, a concern often raised is that inhibitors will fail to function in cells. To test whether the virtual screen yielded cellpermeable inhibitors, we evaluated our compounds against Mycobacterium smegmatis in broth microdilution assays. We focused on this organism, which is often used as a model for pathogenic mycobacteria, because UGM is nonessential in K. pneumoniae 62 and because of the need for new antimycobacterial agents.
Growth curves for M. smegmatis were generated in liquid media in the presence of the most promising UGM inhibitors. Trends in growth inhibition aligned well with each compound's in vitro activities (Figures 3 and 6) . Notably, the MIC of 30 for M. smegmatis was 20 μM (9.7 μg/mL). Compound 30 showed no significant killing of bacterial species lacking a UGM ortholog, such as B. subtilis (MIC = 500 μM) and B strain E. coli (MIC > 500 μM; data not shown). Cytotoxicity of 30 with HEK293 cells (Figure S16 ) was observed only at the high concentrations (LD 50 ∼ 100 μM or 47.5 μg/mL) at which the compound aggregates.
We next evaluated compounds for activity against pathogenic M. tuberculosis H37Rv. We employed a disk diffusion assay to compare control bacterial strains to mycobacteria (Figure 6 ). Compound 30 out-performed others tested in the series, significantly inhibiting growth of virulent M. tuberculosis. No zone of inhibition for BL21(DE3) E. coli was observed. These results are consistent with the lack of UGM expression in B strain E. coli. They further indicate that, compared to the previous lead ED103, compound 30 is much more potent against M. tuberculosis ( Figure 6 ). The finding that triazolothiadiazine 30 exhibited enzyme-inhibitory activity in solution and also antimycobacterial activity in cells is notable. The data add to the growing evidence that UGM is a novel antimycobacterial drug target, and they suggest that triazolothiadiazine inhibitors can serve as leads. The challenges of penetrating the mycobacterial cell wall are substantial, 7 so the efficacy of the identified compounds against M. smegmatis and M. tuberculosis is especially notable.
Comparing Docking and HTS Libraries. To understand why virtual screening gave rise to more productive UGM leads than our MLSMR screen, we assessed the chemical similarity of compounds in the docking and MLSMR libraries. Of the many options available for measuring chemical similarity, we selected an ECFP4-based Tanimoto-coefficient (Tc), wherein 1 indicates identical molecules and values lower than 0.35 typically mean the two molecules are of distinct chemotypes. 63 Of the 4.6 million molecules docked, only 560 000 (12.3%) compounds had a Tc < 0.5 from the closest molecule in the MLSMR library. By these criteria, there was structural overlap in the two libraries, though there were many more molecules, and therefore finer granularity, in the docked library. The chemotypes can also be compared by clustering. Clustering MLSMR alone at 60% similarity resulted in 42 683 clusters, while clustering the union of the two libraries resulted in 175 501 clusters. The new 133 000 clusters represent chemotypes present only in the docking library; therefore, they provide a measure of the increased chemical space afforded by the structure-based approach.
Although docking hits 6, 8, and 10 themselves were not directly assayed in HTS, close analogs of these compounds were present in the screened MLSMR library (Table 2) . When we retested these MLSMR analogs in the assays used to evaluate the primary docking hits; the analogs had comparable levels of UGM inhibition as their virtual screening counterparts ( Figure 7 ). As these molecules were not identified as hits in the MLSMR screen, they represent HTS false negatives. These results suggest that suitable chemotypes for inhibition of nucleotide-sugar-dependent enzymes are not necessarily absent from screening libraries. Rather, the stringency that is built into HTS assays to make them reproducible and rapid and to limit promiscuous activities can lead researchers to overlook the weaker binding hits that may be evolved to useful leads. b Tanimoto coefficient (Tc) between docking hit and analog using ECFP4 fingerprints as implemented in Pipeline Pilot (version 6.1; SciTegic Inc., San Diego, CA). This is a common chemical similarity measure ranging from 0 to 1, where 1 indicates identical molecules, and values lower than 0.35 typically mean the two molecules are of distinct chemotypes.
c Closest analog out of the subset of anionic compounds in the MLSMR library. Figure 7 . Inhibition of K. pneumoniae UGM by closest anionic analogs to docking hits in the empirically screened MLSMR library. Compounds were analyzed at 100 μM in the presence and absence of detergent to rule out nonspecific small molecule aggregation-based inhibition. See Table 2 for chemical structures and similarity scoring of the tested MLSMR compounds. Error bars represent standard deviation (n = 2).
Given our results, it is interesting to compare our HTS campaigns to the docking screen from a technical perspective. In total, almost 400 000 molecules have been tested empirically by HTS against the UGMs from K. pneumoniae and M. tuberculosis. Three active inhibitor chemotypes have been obtained with affinities ranging from 10 to 150 μM. Conversely, structure-based docking of a 10-fold larger library revealed three new inhibitor classes, all of which are dissimilar to those discovered by HTS and to each other ( Figure 2 , Figure S1 ; Tc < 0.32 for docking hits to any previously known inhibitor). These findings suggest that the identified compounds could not have been discovered by ligand-based screening methods, such as pharmacophore modeling. 64 Together, our data are consistent with the growing body of literature that suggests virtual screening and HTS are complementary. 37, 58, 65, 66 Conclusions. A virtual screen afforded triazolothiadiazines that inhibit UGM and are more potent, specific, and active against mycobacteria than other inhibitors reported to date. Our X-ray structure of the UGM−compound 22 complex can guide the generation of new antimycobacterial agents and potent probes of UGM function. Moreover, the activity of our triazolothiadiazine inhibitors against C. elegans UGM should yield reagents for constructing novel probes and effective experimental screens for a broader scope of UGMs. Perhaps most importantly, our study suggests that the success of virtual screening with UGM compared to HTS was not due to exploring a larger chemical spacerather it provided the opportunity to reclaim HTS false negatives. These results highlight the complementarity of HTS and docking 66 and provide a way forward for inhibitor discovery for nucleotidesugar-dependent enzymes, an important and recalcitrant class of proteins.
■ EXPERIMENTAL SECTION
Methods are summarized briefly below. See the Supporting Information for experimental detail. DLS, aggregation screens, X-ray crystallography, and mammalian cytotoxicity assays are described exclusively in the Supporting Information.
Molecular Docking and Ligand Selection. Docking was performed with DOCK3.6. 41, 42 Sampling parameters were varied and assessed by enrichment of known ligands over decoys. The docking-property-matched decoys were calculated by the DUD-E server. 49 For the final virtual screen, ZINC's 35 pregenerated lead-like subset (subset 1), containing 4.6 million molecules, was docked. The top 500 molecules from the docking screen were filtered using Marvin (ChemAxon), a SMARTS filter, and chemical logic. Compound similarity was calculated using ECFP4-based Tanimoto coefficients 67 as implemented in Pipeline-Pilot. 68 See the Supporting Information for compound sources.
Recombinant Protein Expression and Purification. UGM homologues from K. pneumoniae and M. tuberculosis were produced in E. coli and purified as previously described 20, 21 with slight modifications (see the Supporting Information). C. diphtheriae UGM was cloned into the pMALc5x vector, expressed in E. coli ER2523, and purified using a previously described procedure for the K. pneumoniae UGM. 45 UGM in Vitro Inhibition. The enzymatic activity of each recombinant UGM was monitored using an HPLC-based assay. 10, 52 Small molecules were added from DMSO stocks to a final concentration of 1% DMSO. Reactions were analyzed using a CarboPac PA-100 column (Thermo Scientific) on an Agilent 1260 Infinity HPLC using an isocratic elution.
Small Molecule Binding to UGM. A fluorescence polarization assay was used to measure ligand binding to K. pneumoniae UGM, 19, 20 and data were fit to a one-site binding nonlinear regression in GraphPad Prism 6.
Microbroth Dilution Assay. A starter culture of M. smegmatis mc 2 155 (ATCC 700084) was grown to saturation at 30°C in Middlebrook 7H9 broth with albumin dextrose catalase enrichment and 0.05% Tween 80. Small molecules or DMSO (vehicle control) were added to wells of a sterile 96-well plate. Cells were diluted into fresh media and added to the plate to a final 1% DMSO concentration. After growth (46 h) in a 30°C shaking incubator, cell viability was measured using an alamarBlue assay (Invitrogen).
Disk Diffusion Assay. Saturated starter cultures were diluted to an OD 600 of 0.02 in fresh media and plated. Sterile disks (6 mm diameter, Whatman) infused with compound (400 nmol) were placed on the surface of the inoculated solid media. E. coli plates were incubated at 37°C overnight. Plates with M. smegmatis were incubated 3 additional days at room temperature, and M. tuberculosis plates were incubated 2 weeks at 37°C. Zones of inhibition were measured from the outer edge of the cloning disk to the border of cell growth.
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